Clinical observation on the treatment of childhood refractory idiopathic thrombocytopenic purpura with Dihuang Zhixue Capsule (地黄止血胶囊)

Qing-chi Liu; Wei-hai Wu; Da-yong Wu; Xin-wang Feng; Ya-hui Ma; Jian-ying Li; Yu-hui Pang; Shu-hua Song

doi:10.1007/s11655-008-0132-2

Your Location：

Home >

Browse articles >

Clinical observation on the treatment of childhood refractory idiopathic thrombocytopenic purpura with Dihuang Zhixue Capsule (地黄止血胶囊)

Updated：2021-08-27

- Clinical observation on the treatment of childhood refractory idiopathic thrombocytopenic purpura with Dihuang Zhixue Capsule (地黄止血胶囊)
- Chinese Journal of Integrative Medicine Vol. 14, Issue 2, Pages: 132-136(2008)
- Affiliations：
  
  Department of Hematology, Ping’an Hospital, Shijiazhuang Municipal Doctorial Institute of Hematology,Shijiazhuang,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-008-0132-2
  CLC：
- Published：2008，
  
  Published Online：6 August 2008，
Scan for full text
Liu, Qc., Wu, Wh., Wu, Dy. et al. Clinical observation on the treatment of childhood refractory idiopathic thrombocytopenic purpura with Dihuang Zhixue Capsule (地黄止血胶囊)., Chin. J. Integr. Med. 14, 132–136 (2008). https://doi.org/10.1007/s11655-008-0132-2

Qing-chi Liu, Wei-hai Wu, Da-yong Wu, et al. Clinical observation on the treatment of childhood refractory idiopathic thrombocytopenic purpura with Dihuang Zhixue Capsule (地黄止血胶囊). [J]. Chinese Journal of Integrative Medicine 14(2):132-136(2008)
Liu, Qc., Wu, Wh., Wu, Dy. et al. Clinical observation on the treatment of childhood refractory idiopathic thrombocytopenic purpura with Dihuang Zhixue Capsule (地黄止血胶囊)., Chin. J. Integr. Med. 14, 132–136 (2008). https://doi.org/10.1007/s11655-008-0132-2 DOI：

Qing-chi Liu, Wei-hai Wu, Da-yong Wu, et al. Clinical observation on the treatment of childhood refractory idiopathic thrombocytopenic purpura with Dihuang Zhixue Capsule (地黄止血胶囊). [J]. Chinese Journal of Integrative Medicine 14(2):132-136(2008) DOI： 10.1007/s11655-008-0132-2.

摘要

To observe the clinical effect of Dihuang Zhixue Capsule (地黄止血胶囊

DZC

a Chinese preparation for cooling blood and dispelling toxic substances) in the treatment of childhood refractory idiopathic thrombocytopenic purpura (RITP)

with cyclosporin A (CsA) used as the control. Forty-one children of RITP were randomized into the treated group and the control group. The 21 patients in the treated group were orally given 2 to 3 DZC capsules each time

thrice a day and the 20 in the control group were given 3 mg/kg CsA per day

with 3 months as one therapeutic course. The therapeutic efficacy

platelet count and adverse reaction in the two groups were compared at the end of the course. (1) In the treated group

1 (4.8%) patient was evaluated as cured

3 (14.3%) as markedly effective

5 (23.8%) as effective

5 (23.8%) as improved

7 (33.3%) as ineffective

with the total effective rate being 66.7%; while in the control group

the corresponding numbers were 0

2 (10.0%)

3 (15.0%)

13 (65.0%) and 35.0%

respectively

showing statistical significance in difference between the total effective rates of the two groups (ξ2=4.11

P=0.0426). (2) As compared with the baseline

the platelet count increased in both groups after 2 months’ treatment (P<0.05). After 3 months’ treatment

the platelet count was higher in the treated group than in the control group (P<0.05). (3) The improvement of hemorrhage in the treated group after 8 weeks’ treatment was better than that in the control group (P<0.05). (4) No apparent adverse reaction was observed in the treated group

while in the control group

hirsutism was shown in 15 cases; gingival hyperplasia in 10; digestive reaction in 5

liver function impairment in 5

hypertension in 2 and renal impairment in 2. The therapeutic efficacy of DZC is better than that of CsA

and DZC shows good compliance but brings no obvious adverse reaction.

Abstract

To observe the clinical effect of Dihuang Zhixue Capsule (地黄止血胶囊

DZC

a Chinese preparation for cooling blood and dispelling toxic substances) in the treatment of childhood refractory idiopathic thrombocytopenic purpura (RITP)

thrice a day and the 20 in the control group were given 3 mg/kg CsA per day

with 3 months as one therapeutic course. The therapeutic efficacy

platelet count and adverse reaction in the two groups were compared at the end of the course. (1) In the treated group

1 (4.8%) patient was evaluated as cured

3 (14.3%) as markedly effective

5 (23.8%) as effective

5 (23.8%) as improved

7 (33.3%) as ineffective

with the total effective rate being 66.7%; while in the control group

the corresponding numbers were 0

2 (10.0%)

3 (15.0%)

13 (65.0%) and 35.0%

respectively

showing statistical significance in difference between the total effective rates of the two groups (ξ2=4.11

P=0.0426). (2) As compared with the baseline

the platelet count increased in both groups after 2 months’ treatment (P<0.05). After 3 months’ treatment

while in the control group

hirsutism was shown in 15 cases; gingival hyperplasia in 10; digestive reaction in 5

liver function impairment in 5

hypertension in 2 and renal impairment in 2. The therapeutic efficacy of DZC is better than that of CsA

and DZC shows good compliance but brings no obvious adverse reaction.

关键词

refractory idiopathic thrombocytopenic purpuraDihuang Zhixue Capsulecooling blood and dispelling toxic substances

Keywords

refractory idiopathic thrombocytopenic purpuraDihuang Zhixue Capsulecooling blood and dispelling toxic substances

references

Kappers-Klunne MC, van’t Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol 2001;114:121–125.

Emilia G, Morselli M, Luppi M, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood 2002;99:1482–1485.

Perrotta S, Amendola G, Locatelli F, et al. Treatment with short-term, high-dose cyclosporin A in children with refractory chronic idiopathic thrombocytopenic purpura. Br J Haematol 2003;121:143–147.

Duan T, Chang Y, Liu JL. Short-term observation of cyclosporin A in the treatment of refractory chronic idiopathic thrombocytopenic purpura. Chin J Intern Med (Chin) 2000;39(9):630.

Wang CQ, Li D. Observation of cyclosporin A in the treatment of refractory chronic idiopathic thrombocytopenic purpura. Modern Med J (Chin) 2002;30(2):94–95.

Yang N, Cai J. Clinical observation of cyclosporin A in the treatment of refractory chronic idiopathic thrombocytopenic purpura. J Pract Diagn Ther (Chin) 2002;16(4):286–287.

Zhang ZN, ed. Standard for diagnosis and therapeutic efficacy of hematopathy. 2nd ed. Beijing: Science Press, 1998: 279–282.

Cines DB, Blanchette VS. Immue thrombocytopenic purpura. N Engl J Med 2002; 346: 995–1008.

Kahan BD. Cyclosporine. N Engl Med 1989;321:1725–1738.

Ma J, Fan QL. The influence of dried Radix Rehmanniae on I a antigen expression of peritoneal macrophage in the mice model of yin defi cincy induced by corticosterone. Pharmacol Clin Chin Materia Med (Chin) 1998;14 (2):22–24.

Wang B, Ge ZD, Zhou AW, et al. Effects of total glucosides of mudan cortex on functions of three types of immune cells in vitro. Chin Pharmacol Bull (Chin) 1999;15(1):63–65.

Zhou XL, Li YW, Li FC, et al. The experimental study of panax natoginseng saponins on immune functions of rats. J Guangxi Med Univ (Chin) 2001;18(3):360–361.

Yang SL, Liu F. Suppressive effects of rubidate on immune function. Chin Pharmacol Bull (Chin) 1996;12(5):447.

Han JY, Tan DH, Wang MW. Study on hemostatic effect of hydrolysate of Bubalus Bubalis. Pract Pharm Clin Rem (Chin) 2004;7(3):17–18.

FULL TEXT LINK

More>

Views

407

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰